Comparative Pharmacology
Head-to-head clinical analysis: HICON versus OXYBUTYNIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HICON versus OXYBUTYNIN.
HICON vs OXYBUTYNIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Unknown; possibly involves modulation of hypothalamic thermoregulatory center.
Oxybutynin is an anticholinergic agent that competitively antagonizes muscarinic acetylcholine receptors (M1, M2, M3 subtypes) in the bladder detrusor muscle, inhibiting involuntary contractions and increasing bladder capacity.
HICON (norepinephrine) 0.05-0.5 mcg/kg/min IV continuous infusion, titrated to blood pressure.
5 mg orally 2-3 times daily; maximum 5 mg 4 times daily. Extended-release: 5-10 mg orally once daily; maximum 30 mg/day. Transdermal: 3.9 mg/day patch applied every 3-4 days. Topical gel: 1 g (3 pumps) applied once daily.
None Documented
None Documented
Clinical Note
moderateOxybutynin + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Oxybutynin."
Clinical Note
moderateOxybutynin + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Oxybutynin."
Clinical Note
moderateOxybutynin + Cyclosporine
"The metabolism of Cyclosporine can be decreased when combined with Oxybutynin."
Clinical Note
moderateOxybutynin + Fluconazole
Terminal half-life: 12-18 hours; prolonged to 24-36 hours in renal impairment (CrCl <30 mL/min)
Terminal half-life: 12-13 hours (range 7-20 hours) in healthy adults. In elderly, half-life may be prolonged due to reduced clearance.
Renal: 70% as unchanged drug; biliary/fecal: 25% as metabolites; 5% other
Primarily hepatic metabolism; less than 1% excreted unchanged in urine. Metabolites are mainly excreted renally (50%) and fecally (40%).
Category C
Category A/B
Anticholinergic
Anticholinergic
"The metabolism of Fluconazole can be decreased when combined with Oxybutynin."